Ratings Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Market Closed - Nyse Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
286.9 ^USD	+1.72%		-0.12%	-11.16%

May. 30	Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024	CI
May. 14	Transcript : Bio-Rad Laboratories, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:05 PM

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company appears to be poorly valued given its net asset value.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
With an expected P/E ratio at 27.85 and 28.66 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
BIO-RAD LABORATORIES, INC.	-11.16%	8.15B	B-
ABBOTT LABORATORIES	-7.16%	178B	C+
MEDTRONIC PLC	-1.23%	107B	C
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B	A
DEXCOM, INC.	-4.28%	47.23B	B-
CENCORA, INC.	+10.32%	44.62B	B-
HOYA CORPORATION	+8.14%	42.5B	B+
TERUMO CORPORATION	+15.53%	25.22B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B	A-
ZIMMER BIOMET HOLDINGS, INC.	-5.38%	23.69B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes